Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic hematopoietic stem cells (Nationwide Children's Hospital)
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic hematopoietic stem cells are used as a cellular immunotherapy for pediatric patients with relapsed or refractory high-risk neuroblastoma. This therapeutic approach involves the transplantation of hematopoietic stem cells from a human leukocyte antigen (HLA) matched sibling or unrelated donor following a reduced-intensity conditioning (RIC) regimen, which typically includes agents like fludarabine, busulfan, and anti-thymocyte globulin. The primary therapeutic mechanism is the Graft-versus-Tumor (GVT) effect, where donor-derived immune cells—specifically T cells and Natural Killer (NK) cells—recognize and eliminate residual host neuroblastoma cells. The specific protocol developed at Nationwide Children's Hospital (NCT00660933) focuses on evaluating the role of NK cells and Killer-cell Immunoglobulin-like Receptor (KIR) mismatches between the donor and recipient to enhance the anti-tumor response while minimizing transplant-related toxicity.
- Other names
- allogeneic hematopoietic stem cell transplantationAllo-HSCTallogeneic stem cell transplant
Beyond the preview
Go deeper on allogeneic hematopoietic stem cells (Nationwide Children's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic hematopoietic stem cells (Nationwide Children's Hospital).